The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000441314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
12/02/2026
Date registered
Help: Date registered
9/04/2026
Date last updated
Help: Date last updated
9/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
9/04/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
A study of SIR2501 in participants with amyotrophic lateral sclerosis and in participants receiving paclitaxel chemotherapy to evaluate safety and to prevent chemotherapy-induced peripheral neuropathy
Scientific title
A Phase Ib/IIa, open-label study to evaluate the safety, tolerability, pharmacokinetics, and activity of SIR2501 in participants with amyotrophic lateral sclerosis and in participants with solid tumours receiving paclitaxel-based chemotherapy for the prevention of chemotherapy-induced peripheral neuropathy (Protocol SIR2501-GLB-201)
Additional trial identifiers [1] 316519 0
SIR2501-GLB-201
Universal Trial Number (UTN)
Trial acronym
SIR2501-ALS-CIPN
Related trial records

Health condition
Health condition(s) studied:
Amyotrophic lateral sclerosis (ALS) 340656 0
Chemotherapy-induced peripheral neuropathy (CIPN) 340657 0
Condition category
Condition code
Neurological 336845 336845 0 0
Neurodegenerative diseases
Cancer 336850 336850 0 0
Any cancer
Neurological 336851 336851 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
SIR2501 is an orally administered investigational small molecule.

This is a Phase Ib/IIa, open-label, multisite study conducted in two parts:

Part A (dose escalation):
Participants will receive SIR2501 orally once daily at escalating dose levels (30 mg, 45 mg, or 60 mg) using a standard 3+3 design to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D).

Part B (dose expansion):
Participants will receive SIR2501 orally once daily at the selected dose to further evaluate safety, tolerability, pharmacokinetics, and activity.

Participants with ALS will receive treatment for 24 weeks.
Participants receiving paclitaxel-based chemotherapy will receive treatment for approximately 12–18 weeks.


Study Structure (Parts A and B):
This is a Phase Ib/IIa, open-label, two-part study including two independent patient populations:

Participants with ALS, and

Solid tumour participants receiving paclitaxel-based chemotherapy and at risk of CIPN.

Both ALS and CIPN populations will participate in Part A (dose escalation) and Part B (dose expansion); however, they are treated as separate cohorts throughout.

Participants enrolled in Part A will not automatically continue into Part B.
Part B will enrol separate participants following determination of the RP2D in Part A.

The ALS and CIPN cohorts are analysed independently and will not be compared to each other in either Part A or Part B.
Intervention code [1] 333186 0
Treatment: Drugs
Description of the comparator or control
No control group – single arm study
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344990 0
Incidence of dose-limiting toxicities
Timepoint [1] 344990 0
During the dose-limiting toxicity evaluation period following the first dose of study treatment (approximately first 28 days).
Primary outcome [2] 344991 0
Change in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised score
Timepoint [2] 344991 0
From baseline to Week 24, assessed at scheduled study visits (approximately every 4 weeks).
Primary outcome [3] 344992 0
Incidence and severity of chemotherapy-induced peripheral neuropathy
Timepoint [3] 344992 0
From baseline through the treatment period (up to approximately 12 to 18 weeks), assessed at each chemotherapy cycle and scheduled study visits.
Secondary outcome [1] 457651 0
Change in blood neurofilament light chain (NfL) concentration
Timepoint [1] 457651 0
Baseline to Week 24 (ALS cohort), assessed at Weeks 8, 16 and 24.
Secondary outcome [2] 457652 0
Pharmacokinetics of SIR2501
Timepoint [2] 457652 0
Baseline (pre-dose on Day 0), and post-dose at 2 hours (±30 minutes), 4 hours (±30 minutes) and 6 hours (±30 minutes) on Day 0; pre-dose trough samples at Week 4 (Day 28) and Week 12 (Day 84); and at Week 24 (Day 168) pre-dose trough and 4 hours (±30 minutes) post-dose.
Secondary outcome [3] 457653 0
Incidence and severity of chemotherapy-induced peripheral neuropathy (assessed as a composite secondary outcome)
Timepoint [3] 457653 0
During treatment period (up to 18 weeks) During the treatment period (up to 18 weeks), assessed at each chemotherapy cycle (approximately every 3 weeks) and at scheduled study visits throughout treatment. If you want a slightly clearer registry-style version: During the treatment period (up to 18 weeks), assessed at each chemotherapy cycle (approximately every 3 weeks) and at the end of treatment visit.

Eligibility
Key inclusion criteria
For ALS cohort:

Adults aged 18–70 years

Diagnosis of amyotrophic lateral sclerosis (ALS)

Able to provide informed consent

For CIPN cohort:

Adults aged 18–75 years

Diagnosis of a solid tumour receiving paclitaxel-based chemotherapy

At risk of developing chemotherapy-induced peripheral neuropathy

Able to provide informed consent
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Significant uncontrolled medical conditions

Known hypersensitivity to study drug components

Participation in another interventional clinical trial

Any condition that, in the investigator’s opinion, would make participation unsafe

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1 / Phase 2
Type of endpoint/s
Safety
Statistical methods / analysis
Safety analysis will be descriptive. Incidence and severity of adverse events will be summarised by frequency and grade (CTCAE). Pharmacokinetic parameters will be summarised using descriptive statistics. Biomarker changes will be analysed using change-from-baseline methods.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment outside Australia
Country [1] 27822 0
China
State/province [1] 27822 0

Funding & Sponsors
Funding source category [1] 321132 0
Commercial sector/Industry
Name [1] 321132 0
Sironax, Ltd
Country [1] 321132 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Sironax, Ltd
Address
Country
Australia
Secondary sponsor category [1] 323848 0
None
Name [1] 323848 0
Address [1] 323848 0
Country [1] 323848 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319663 0
Bellberry Human Research Ethics Committee A
Ethics committee address [1] 319663 0
Ethics committee country [1] 319663 0
Australia
Date submitted for ethics approval [1] 319663 0
12/08/2025
Approval date [1] 319663 0
25/09/2025
Ethics approval number [1] 319663 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148034 0
A/Prof Steve Vucic
Address 148034 0
Brain and Nerve Research Centre Clinical Sciences Building 20 Concord Repatriation General Hospital Hospital Road Concord NSW 2139
Country 148034 0
Australia
Phone 148034 0
+61 2 9767 8461
Fax 148034 0
Email 148034 0
Contact person for public queries
Name 148035 0
Dr Steve Vucic
Address 148035 0
Brain and Nerve Research Centre Clinical Sciences Building 20 Concord Repatriation General Hospital Hospital Road Concord NSW 2139
Country 148035 0
Australia
Phone 148035 0
+61 2 9767 8461
Fax 148035 0
Email 148035 0
Contact person for scientific queries
Name 148036 0
Dr Steve Vucic
Address 148036 0
Brain and Nerve Research Centre, Concord Hospital
Country 148036 0
Australia
Phone 148036 0
+61 2 9767 8461
Fax 148036 0
Email 148036 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.